These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605 [TBL] [Abstract][Full Text] [Related]
12. Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified α-Synuclein. Chen H; Zhao YF; Chen YX; Li YM ACS Chem Neurosci; 2019 Feb; 10(2):910-921. PubMed ID: 30628768 [TBL] [Abstract][Full Text] [Related]
13. Structural brain changes in Ser129-phosphorylated alpha-synuclein rats based on voxel-based morphometry. Wang J; Tan Y; Peng Q; Zeng W; Yang X; Chen C; Wu Y; Xu Y; Cao X Behav Brain Res; 2020 Sep; 393():112786. PubMed ID: 32592738 [TBL] [Abstract][Full Text] [Related]
14. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models. Sato H; Kato T; Arawaka S Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528 [TBL] [Abstract][Full Text] [Related]
15. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease. Haque ME; Akther M; Azam S; Kim IS; Lin Y; Lee YH; Choi DK Br J Pharmacol; 2022 Jan; 179(1):23-45. PubMed ID: 34528272 [TBL] [Abstract][Full Text] [Related]
16. Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease. Oueslati A; Paleologou KE; Schneider BL; Aebischer P; Lashuel HA J Neurosci; 2012 Feb; 32(5):1536-44. PubMed ID: 22302797 [TBL] [Abstract][Full Text] [Related]
17. Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Ihara M; Yamasaki N; Hagiwara A; Tanigaki A; Kitano A; Hikawa R; Tomimoto H; Noda M; Takanashi M; Mori H; Hattori N; Miyakawa T; Kinoshita M Neuron; 2007 Feb; 53(4):519-33. PubMed ID: 17296554 [TBL] [Abstract][Full Text] [Related]
18. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. Chen L; Periquet M; Wang X; Negro A; McLean PJ; Hyman BT; Feany MB J Clin Invest; 2009 Nov; 119(11):3257-65. PubMed ID: 19855133 [TBL] [Abstract][Full Text] [Related]
19. Neurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions. Gadhavi J; Patel M; Bhatia D; Gupta S Biochimie; 2022 Jan; 192():38-50. PubMed ID: 34582997 [TBL] [Abstract][Full Text] [Related]
20. The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease. Galvagnion C J Parkinsons Dis; 2017; 7(3):433-450. PubMed ID: 28671142 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]